Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC
Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.
Related Articles
Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer
Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer
Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.
The OncFive: Top Oncology Articles for the Week of 12/18
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
Ultra-Sensitive Duplex Sequencing Improves Diagnostic Capabilities in Indolent Systemic Mastocytosis
Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.
FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC
Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.
Sharing AI insights without sharing patient data
The new Cancer AI Alliance includes Fred Hutch, Dana-Farber, Memorial Sloan Kettering, The Sidney Kimmel Comprehensive Cancer Center and the Whiting School of Engineering at…
Surgeon General Aims to Reduce Alcohol-Related Cancers in the US
“Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States,” said…
2/21/2025 – 2025 Gastrointestinal Oncology Symposium
Medical information is constantly being updated and new clinical trials reported. Treatment algorithms and clinical guidelines are modified year-round at specialty conferences and by national…
